Arthur S. Kirsch – Chairman
Arthur S. Kirsch is Chairman of the Board of Aralez Pharmaceuticals Inc. and served in this role with the company’s predecessor, POZEN Inc., since June 1, 2015 and on the Board since May 2004. He is chairman of the audit committee and a member of the compensation and governance/nominating committees. Mr. Kirsch has over 30 years of experience working in the equity capital markets and has extensive knowledge of the healthcare and life sciences field. Since 2005 he has been a Senior Advisor with GCA Savvian, LLC (formerly Perseus Group, LLC), an investment bank. Prior to GCA Savvian he was a founding member and managing director of Vector Securities, LLC, an investment and merchant banking firm.
Mr. Kirsch has also held senior leadership positions at Prudential Vector Healthcare Group, a unit of Prudential Securities, Inc., and at Vector Securities International, Inc. Before joining Vector in 1995, he was president and chief executive officer of NatWest Securities U.S. and director of the Global Equity Division of Drexel Burnham Lambert. Mr. Kirsch also serves on the Board of Directors for Immunomedics.
Mr. Adams is Chief Executive Officer and a Director of Aralez Pharmaceuticals Inc. and served in this role with the company’s predecessor, POZEN Inc., since June 1, 2015. Prior to joining the company, Mr. Adams served as Chief Executive Officer and President of Auxilium Pharmaceuticals, Inc. from December 2011 until its acquisition by Endo International plc in January 2015 for $2.6 billion. Under his leadership, Auxilium transformed into a men’s healthcare company and broadened its portfolio from two to twelve through the strategic corporate acquisition of Actient Holding LLC and product in-licensing. Prior to joining Auxilium, Mr. Adams served as Chairman and Chief Executive Officer of Neurologix, Inc., a company focused on development of multiple innovative gene therapy development programs. Before Neurologix, Mr. Adams served as President and Chief Executive Officer of Inspire Pharmaceuticals, Inc., where he oversaw the commercialization and development of prescription pharmaceutical products and led the company through a strategic acquisition by global pharmaceutical leader Merck & Co., Inc. in May 2011 for $430 million. Prior to Inspire, Mr. Adams served as President and Chief Executive Officer of Sepracor Inc. from December 2006 until its acquisition by Dainippon Sumitomo Pharma Co. in February 2010 for $2.6 billion. Under his leadership, Sepracor conducted multiple strategic corporate development activities, including the in-licensing of seven products and out-licensing deals with two major pharmaceutical companies, prior to its acquisition by Dainippon Sumitomo Pharma Co.
Prior to joining Sepracor, Mr. Adams was President and Chief Executive Officer of Kos Pharmaceuticals, Inc. from 2002 until the acquisition of the company by Abbott Laboratories in December 2006 for $3.7 billion. During his tenure he led the transformation of Kos into a fully integrated and profitable pharmaceutical company with annual revenues approaching $1 billion. During his 30 years of experience, Mr. Adams also held general management and senior marketing positions at ICI (now part of AstraZeneca), SmithKline Beecham and Novartis. He has extensive international and national experience and has been instrumental in launching major global brands in addition to driving successful corporate development activities encapsulating financing, product and company acquisitions, in-licensing and company M&A activities.
Mr. Adams graduated from the Royal Institute of Chemistry at Salford University in the U.K. Mr. Adams serves as Chairman of the Board of AcelRx Pharmaceuticals and recently served as a director of Amylin Pharmaceuticals.
Jason M. Aryeh
Jason M. Aryeh serves as a member of the Board of Directors of Aralez Pharmaceuticals Inc. since February 5, 2016. Mr. Aryeh is the Founder and Managing General Partner of JALAA Equities, LP, a private hedge fund focused on the life-sciences sector, and has served in such capacity since 1997. Mr. Aryeh serves as the Chairman of the Board of Directors of Novelion Therapeutics (NASDQ: NVLN) and serves on its Corporate Nominating & Governance Committee. Mr. Aryeh serves on Ligand Pharmaceuticals (NASDQ: LGND) Board of Directors and serves as the Chairman of its Corporate Nominating & Governance Committee and as a member of its Compensation Committee. Mr. Aryeh also serves as a Directors of the Cystic Fibrosis Foundation’s Therapeutic Board.
Mr. Aryeh earned a B.A. in economics, with honors, from Colgate University, and is a member of the Omnicron Delta Epsilon Honor Society in economics.
Kenneth B. Lee, Jr.
Kenneth B. Lee, Jr. serves as a member of the Board of Directors of Aralez Pharmaceuticals Inc. and served in this role with the company’s predecessor, POZEN Inc., since December 2002. He is chairman of the compensation committee and a member of the audit committee. Mr. Lee is a managing member of Hatteras Venture Partners, a venture capital fund focusing on life sciences companies. Mr. Lee spent 29 years with Ernst & Young, primarily in the Palo Alto Office. He ran the Firms Life Sciences Practice in the US and was Co-Chair of the International Life Sciences Practice. He is a co-founder of the National Conference on Biotechnology Ventures and co-authored the Ernst & Young Life Sciences Annual Report for many years. and serves as a director of CV Therapeutics and Abgenix and Inspire Pharmaceuticals. Mr. Lee also advised biotechnology and pharmaceutical companies throughout the world on a wide range of financial and strategic planning issues. After retiring from Ernst & Young, he served on the boards of Abgenix, CV Therapeutics, Inspire Pharmaceuticals, Maxygen and OSI Pharmaceuticals. Mr. Lee currently serves on the boards of Aralez and Biocryst Pharmaceuticals.
Mr. Lee received a Bachelor of Arts degree from Lenoir-Rhyne College and an MBA from the University of North Carolina at Chapel Hill.
F. Martin Thrasher
Mr. Thrasher serves as a member of the Board of Directors of Aralez Pharmaceuticals Inc. since February 5, 2016. Mr. Thrasher is a seasoned international executive. After graduating from the Richard Ivey School of Business in London ON. Thrasher spent over 30 years working around the globe for companies such as General Foods, McCormick & Co, Campbell Soup Co. and ConAgra Foods Inc. Mr. Thrasher lived and worked in Canada, Australia, Belgium and the USA. His responsibilities with Campbell Soup Co. included positions as President, International Grocery and President, North America Grocery. At ConAgra Foods Inc., he was President of the Retail Products Co, a $9 billion business with over 30,000 employees. Currently, Mr. Thrasher is President of FMT Consulting, a boutique advisory and consulting firm. Mr. Thrasher was chosen as a Director in light of his significant international business experience with Fortune 500 companies.
Neal F. Fowler
Neal F. Fowler serves as a member of the Board of Directors of Aralez Pharmaceuticals Inc. and served in this role with the company’s predecessor, POZEN Inc., since June 2010 and as a member of the compensation and governance/nominating committees. Mr. Fowler is Chief Executive Officer of Liquidia Technologies, Inc., and led the efforts to create two spin-out companies from Liquidia, Envisia Therapeutics and Lq3 Pharmaceuticals. Mr. Fowler joined Liquidia in 2008 after seven successful years at Johnson & Johnson (J&J). While at J&J, Mr. Fowler served as President of Centocor, Inc., a multi-billion dollar subsidiary focused on development and commercialization of industry leading biomedicines used in the treatment of chronic inflammatory diseases. At Centocor, Mr. Fowler prepared the company for the launch of two potential blockbuster products and continued the company’s legacy of double-digit growth for their flagship product REMICADE® (infliximab). Prior to Centocor, Mr. Fowler was President of Ortho-McNeil Neurologics Inc. and Vice President of the central nervous system franchise at Ortho-McNeil Pharmaceuticals. Mr. Fowler joined J&J after a successful 13-year career at Eli Lilly and Company, holding a variety of management positions of increasing responsibility.
Mr. Fowler is a native of Raleigh, NC and received a Bachelor of Science degree in Pharmacy and Masters of Business Administration from the University of North Carolina at Chapel Hill.
Rob Harris serves as a member of the Board of Directors of Aralez Pharmaceuticals Inc. since February 5, 2016. Mr. Harris has over 35 years of pharmaceutical industry experience in both Canada and the United States in sales, marketing, business development and general management. Mr. Harris most recently served as President and CEO of Tribute Pharmaceuticals. Prior to co-founding Tribute Pharmaceuticals, Rob was the President & CEO of Legacy Pharmaceuticals Inc. Mr. Harris also has previous experience at Biovail Corporation where as VP of Business Development he was involved, led and successfully concluded numerous business development transactions, including the licensing of new chemical entities, the acquisition of mature products, the completion of co-promotion deals, distribution agreements, product development and reformulation transactions. Mr. Harris joined Biovail in 1997 as the GM of Biovail Pharmaceuticals Canada at a time when the company experienced rapid growth in the Canadian division. Before Biovail, Mr. Harris worked in various senior commercial management positions during his twenty-year tenure at Wyeth (Ayerst) including its animal health group and has been involved in numerous product launches during his career.
Seth A. Rudnick, M.D.
Seth A. Rudnick serves as a member of the Board of Directors of Aralez Pharmaceuticals Inc., and served in this role with the company’s predecessor, POZEN Inc., since July of 2011. He is a member of the audit and governance/nominating committees. Dr. Rudnick is retired from Canaan Partners, where he built the global venture capital firm’s capability in biopharmaceutical investing. He has led many drug discovery and development projects throughout his career in the pharmaceutical and biotech industries, which spans research, development, clinical trials analysis and biotechnology as well as founding and growing start-up companies. Prior to joining Canaan Partners, Dr. Rudnick served as Chief Executive Officer and Chairman of CytoTherapeutics, a company developing stem cell-based therapies to combat chronic diseases. He also helped found and served as the Head of Research and Development for Ortho Biotech, a division of Johnson & Johnson that provides life-improving products to individuals with a focus on cancer and chronic illnesses. He is currently a Clinical Adjunct Professor of Medicine at University of North Carolina, Chapel Hill, teaching and advising faculty members on biotechnology issues. Dr. Rudnick also serves on the Board of Directors for Liquidia and G1 Therapeutics.